Navigation

The Company
Our Science
Our Medicine
- Our Medicine
- Advanced Malignant PEComa
Pipeline
Expanded Access
Patients
- Overview
- Patient Advocacy
Contact Us

cache

Home cache

Next Post
Previous Post

cache

David Dornan, PhD

January 1, 2020 / Uncategorized

Like this post!

Share the Post

About the Author

Related Posts

cache

Aadi Bioscience Appoints Loretta Itri as Chief Medical Officer

Patients With Severe Pulmonary Arterial Hypertension Treated With ABI-009, nab-Sirolimus, an mTOR Inhibitor: Interim Results From a Phase 1 Clinical Trial

Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa)

Mutational and Biomarker Correlative Analysis of mTOR Pathway Aberrations in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa) Treated With nab-Sirolimus: Results From AMPECT, an Open-Label Phase 2 Registration Trial

cache

Baiteng Zhao, PhD

Comments

Comments are closed.

Next Post
Previous Post

Recent Articles

David Dornan, PhD
Baiteng Zhao, PhD
Characterizing the genomic landscape of malignant perivascular epithelioid cell family of tumors (PEComa-FT) in a real-world population using the Foundation Medicine genomic database
A Phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer
Antitumor activity of nab-sirolimus versus mTOR inhibitors temsirolimus, sirolimus, and everolimus in A549 NSCLC xenografts

Home
Pipeline
Patients
Contact
Careers

Terms & Conditions
Privacy